Extending aromatase inhibitor sensitivity in hormone resistant breast cancer

Angela M.H. Brodie, Gauri J. Sabnis, Saranya Chumsri, Angela M.H. Brodie, Saranya Chumsri, Sara Sukumar, Angela M.H. Brodie

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aromatase inhibitors (AIs) are first-line treatment for ER + breast cancer. However, despite responses initially, some patients can eventually acquire resistance. Moreover, 25% of all breast cancer patients do not express the estrogen receptor (ERα) and are innately resistance. In tumors of mouse models with acquired AI letrozole resistance, expression of ERα was reduced whereas HER2/growth factor signaling was enhanced. Treatment of mice with trastuzumab (HER2 antibody) reduced HER2/p-MAPK but restored ERα expression. The addition of trastuzumab to letrozole treatment when tumors progressed resulted in significantly longer tumor suppression than these drugs alone. Thus, inhibition of both HER2 and ERα signaling pathways was necessary to overcome resistance. In ERα-negative tumors, the receptor has been shown to be silenced by epigenetic modifications. Treatment of MDA-MB-231 ER-negative tumors with a histone deacetylase inhibitor, entinostat (ENT) increased expression of ERα and also aromatase. When ENT was combined with letrozole, tumor growth rate was markedly reduced compared with control tumors. ENT plus letrozole treatment also prevented the colonization and growth of MDA-MB-231 cells in the lung with significant reduction in visible and microscopic foci. These novel strategies could improve treatment for patients with acquired and innate resistance to AIs.

Original languageEnglish (US)
Pages (from-to)97-103
Number of pages7
JournalHormone Molecular Biology and Clinical Investigation
Volume5
Issue number2
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Aromatase Inhibitors
letrozole
Estrogen Receptors
Hormones
Breast Neoplasms
Neoplasms
Therapeutics
Histone Deacetylase Inhibitors
Aromatase
Growth
Epigenomics
Intercellular Signaling Peptides and Proteins
Lung
Antibodies

Keywords

  • aromatase inhibitors
  • breast cancer
  • letrozole
  • trastuzumab

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)
  • Molecular Biology
  • Endocrinology

Cite this

Brodie, A. M. H., Sabnis, G. J., Chumsri, S., Brodie, A. M. H., Chumsri, S., Sukumar, S., & Brodie, A. M. H. (2011). Extending aromatase inhibitor sensitivity in hormone resistant breast cancer. Hormone Molecular Biology and Clinical Investigation, 5(2), 97-103. https://doi.org/10.1515/HMBCI.2011.010

Extending aromatase inhibitor sensitivity in hormone resistant breast cancer. / Brodie, Angela M.H.; Sabnis, Gauri J.; Chumsri, Saranya; Brodie, Angela M.H.; Chumsri, Saranya; Sukumar, Sara; Brodie, Angela M.H.

In: Hormone Molecular Biology and Clinical Investigation, Vol. 5, No. 2, 2011, p. 97-103.

Research output: Contribution to journalArticle

Brodie, Angela M.H. ; Sabnis, Gauri J. ; Chumsri, Saranya ; Brodie, Angela M.H. ; Chumsri, Saranya ; Sukumar, Sara ; Brodie, Angela M.H. / Extending aromatase inhibitor sensitivity in hormone resistant breast cancer. In: Hormone Molecular Biology and Clinical Investigation. 2011 ; Vol. 5, No. 2. pp. 97-103.
@article{67acb92391d5437a838321f4eb685b12,
title = "Extending aromatase inhibitor sensitivity in hormone resistant breast cancer",
abstract = "Aromatase inhibitors (AIs) are first-line treatment for ER + breast cancer. However, despite responses initially, some patients can eventually acquire resistance. Moreover, 25{\%} of all breast cancer patients do not express the estrogen receptor (ERα) and are innately resistance. In tumors of mouse models with acquired AI letrozole resistance, expression of ERα was reduced whereas HER2/growth factor signaling was enhanced. Treatment of mice with trastuzumab (HER2 antibody) reduced HER2/p-MAPK but restored ERα expression. The addition of trastuzumab to letrozole treatment when tumors progressed resulted in significantly longer tumor suppression than these drugs alone. Thus, inhibition of both HER2 and ERα signaling pathways was necessary to overcome resistance. In ERα-negative tumors, the receptor has been shown to be silenced by epigenetic modifications. Treatment of MDA-MB-231 ER-negative tumors with a histone deacetylase inhibitor, entinostat (ENT) increased expression of ERα and also aromatase. When ENT was combined with letrozole, tumor growth rate was markedly reduced compared with control tumors. ENT plus letrozole treatment also prevented the colonization and growth of MDA-MB-231 cells in the lung with significant reduction in visible and microscopic foci. These novel strategies could improve treatment for patients with acquired and innate resistance to AIs.",
keywords = "aromatase inhibitors, breast cancer, letrozole, trastuzumab",
author = "Brodie, {Angela M.H.} and Sabnis, {Gauri J.} and Saranya Chumsri and Brodie, {Angela M.H.} and Saranya Chumsri and Sara Sukumar and Brodie, {Angela M.H.}",
year = "2011",
doi = "10.1515/HMBCI.2011.010",
language = "English (US)",
volume = "5",
pages = "97--103",
journal = "Hormone Molecular Biology and Clinical Investigation",
issn = "1868-1883",
publisher = "Walter de Gruyter GmbH",
number = "2",

}

TY - JOUR

T1 - Extending aromatase inhibitor sensitivity in hormone resistant breast cancer

AU - Brodie, Angela M.H.

AU - Sabnis, Gauri J.

AU - Chumsri, Saranya

AU - Brodie, Angela M.H.

AU - Chumsri, Saranya

AU - Sukumar, Sara

AU - Brodie, Angela M.H.

PY - 2011

Y1 - 2011

N2 - Aromatase inhibitors (AIs) are first-line treatment for ER + breast cancer. However, despite responses initially, some patients can eventually acquire resistance. Moreover, 25% of all breast cancer patients do not express the estrogen receptor (ERα) and are innately resistance. In tumors of mouse models with acquired AI letrozole resistance, expression of ERα was reduced whereas HER2/growth factor signaling was enhanced. Treatment of mice with trastuzumab (HER2 antibody) reduced HER2/p-MAPK but restored ERα expression. The addition of trastuzumab to letrozole treatment when tumors progressed resulted in significantly longer tumor suppression than these drugs alone. Thus, inhibition of both HER2 and ERα signaling pathways was necessary to overcome resistance. In ERα-negative tumors, the receptor has been shown to be silenced by epigenetic modifications. Treatment of MDA-MB-231 ER-negative tumors with a histone deacetylase inhibitor, entinostat (ENT) increased expression of ERα and also aromatase. When ENT was combined with letrozole, tumor growth rate was markedly reduced compared with control tumors. ENT plus letrozole treatment also prevented the colonization and growth of MDA-MB-231 cells in the lung with significant reduction in visible and microscopic foci. These novel strategies could improve treatment for patients with acquired and innate resistance to AIs.

AB - Aromatase inhibitors (AIs) are first-line treatment for ER + breast cancer. However, despite responses initially, some patients can eventually acquire resistance. Moreover, 25% of all breast cancer patients do not express the estrogen receptor (ERα) and are innately resistance. In tumors of mouse models with acquired AI letrozole resistance, expression of ERα was reduced whereas HER2/growth factor signaling was enhanced. Treatment of mice with trastuzumab (HER2 antibody) reduced HER2/p-MAPK but restored ERα expression. The addition of trastuzumab to letrozole treatment when tumors progressed resulted in significantly longer tumor suppression than these drugs alone. Thus, inhibition of both HER2 and ERα signaling pathways was necessary to overcome resistance. In ERα-negative tumors, the receptor has been shown to be silenced by epigenetic modifications. Treatment of MDA-MB-231 ER-negative tumors with a histone deacetylase inhibitor, entinostat (ENT) increased expression of ERα and also aromatase. When ENT was combined with letrozole, tumor growth rate was markedly reduced compared with control tumors. ENT plus letrozole treatment also prevented the colonization and growth of MDA-MB-231 cells in the lung with significant reduction in visible and microscopic foci. These novel strategies could improve treatment for patients with acquired and innate resistance to AIs.

KW - aromatase inhibitors

KW - breast cancer

KW - letrozole

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85021016027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021016027&partnerID=8YFLogxK

U2 - 10.1515/HMBCI.2011.010

DO - 10.1515/HMBCI.2011.010

M3 - Article

VL - 5

SP - 97

EP - 103

JO - Hormone Molecular Biology and Clinical Investigation

JF - Hormone Molecular Biology and Clinical Investigation

SN - 1868-1883

IS - 2

ER -